EndoBarrier Gastrointestinal Liner System 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 GI Dynamics 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2015-10-06
  • 사례 출판 날짜
    2015-10-06
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: gi dynamics endobarrier gastrointestinal liner system the medicines and healthcare products regulatory agency (mhra) of united kingdom has posted a medical device safety alert concerning endobarrier gastrointestinal liner system, packaged, sterile us [part number: 40-10-00624], manufactured by gi dynamics (gid). due to the incidence rate of hepatic abscess (ha) in the united states (us) investigational device exemption endo trial exceeding the established safety threshold of 2%, the study was terminated by gid prior to completion. the manufacturer and the us food and drug administration (fda) have come to a mutual agreement to conclude the endo trial as of 30 july 2015. with seven cases of hepatic abscess in the endo trial, the incidence rate is approximately 3.5%, which exceeds a previously established safety threshold of 2%. the overall historical rate of hepatic abscess in markets outside the us is approximately 0.94% based on experience with approximately 3,200 units shipped commercially since 2009. this rate reflects an increase from 0.49% observed globally two years ago, but is still low and below the 2% threshold established for the treatment. all reported cases of ha that developed after endobarrier implantation have been fully resolved upon device removal. the manufacturer will immediately begin explanting the device from all remaining endo trial participants and closing out the endo trial. the manufacturer expects to complete all explants by the end of october. endobarrier will continue to be available to patients who need it in all countries around the world where it is approved for commercial use. physicians are advised to continue to educate patients on the early signs of ha (e.G., right upper quadrant pain, abdominal pain, fever/chills/malaise) and remind them to seek immediate treatment and resolution to mitigate any complications should they be present. for details, please refer to the mhra website:https://www.Gov.Uk/government/publications/safety-information-from-manufacturers-field-safety-notices/field-safety-notices-28-september-to-2-october-2015 if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 6 october 2015.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: GI Dynamics EndoBarrier Gastrointestinal Liner System
  • Manufacturer

Manufacturer